News
NEWs
All Sinopep News
At Sinopep, we value media interest in our business, services, and capabilities. You're welcome to explore the resources on this page or contact our media relations team for specific inquiries. We’ll make sure you’re connected with the appropriate business leader or subject matter expert.
Multi-receptor agonist peptides represent one of the fastest-growing frontiers in metabolic disease therapeutics. Molecules such as amycretin, a dual GLP-1 and amylin receptor agonist, combine two...
Oral delivery of semaglutide is limited by low membrane permeability and gastrointestinal degradation, restricting unassisted bioavailability to well below one percent, a barrier Rybelsus® overcomes...
This paper describes a reagent-quenching strategy in which a Brønsted acid compound is introduced during the post-deprotection wash to chemically neutralize residual piperidine in situ, converting it...
Reflecting on a strong showing at CPHI China, with gratitude to the entire Sinopep team whose collective effort makes moments like this possible...
Reflecting on a productive week at TIDES USA, where conversations with leaders across the peptide and oligonucleotide space reinforced the momentum behind this rapidly evolving field...
The 21st Drug Discovery Strategic Summit (DDSS) has wrapped, and we're still energized by the conversations and connections made at this year's event...
Non-canonical amino acids present a fundamentally different supply challenge compared to proteinogenic residues. Standard amino acid suppliers operate at high volume for commodity materials; NCAA...
Since its founding in 2004, Sinopep has developed a robust and scalable formulation platform focused on delivering high-quality pharmaceutical products and CDMO solutions. Our recently expanded...
Our new GMP oligonucleotide facility represents a major expansion in our ability to manufacture oligonucleotide API and NCE therapeutics, including antisense oligonucleotides (ASOs) and siRNA, at...
